- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
COA Responds to CMS Proposal to Ease Protections on 6 Drug Classes
Community Oncology Alliance (COA) responded to CMS' proposal to ease restrictions on how Medicare Part D and Medicare Advantage plans dictate access to 6 protected drug classes, calling the decision a potential nightmare for vulnerable patients with cancer.
Community Oncology Alliance (COA) responded to CMS' proposal to ease restrictions on how Medicare Part D and Medicare Advantage plans dictate access to 6 protected drug classes, calling the decision a potential nightmare for vulnerable patients with cancer. According to COA, for the first time ever, Medicare patients with cancer and other serious diseases will no longer have guaranteed access to potentially life-saving drugs and instead will have to go through step therapy and formulary restrictions.
Noting their support of the administration's efforts to lower drug prices, COA argues that weakening or dismantling protected classes of drugs is too far. Read the full press release from Jeff Vacirca, MD, FACP, president of COA.
Mental Health Awareness: Transforming Workplace Support and Engagement
May 20th 2025Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More
